A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. (VICTOR)

Astellas

Status and phase: Completed; Phase 4

Conditions: Urinary Incontinence

Treatments: Drug: tamsulosin; Drug: placebo; Drug: solifenacin succinate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00333112

905-UC-008

Details and patient eligibility

About

A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.

Full description

A 2 arm study ( 1 Active, 1 Placebo) to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men

Enrollment: 398 patients

Sex: Male

Ages: 45+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Symptoms of Overactive Bladder (OAB)

Exclusion criteria

• Current use of antimuscarinic therapy
• Evidence of a urinary tract infection

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

398 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: solifenacin succinate

Drug: tamsulosin

2

Placebo Comparator group

Treatment:

Drug: tamsulosin

Drug: placebo